The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
Merck's targeted lung cancer drug tepotinib wins early access in UK -
Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial - Annals of Oncology
JCM | Free Full-Text | The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer | HTML
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study - The Lancet Oncology
FDA approves Tabrecta for treatment of metastatic NSCLC
Novartis' MET inhibitor Tabrecta wins permit for lung cancer in Korea < Pharma < 기사본문 - KBR
Met Kinase Inhibitor | CAS 658084-23-2 | SCBT - Santa Cruz Biotechnology
Safety and Tolerability of c-MET Inhibitors in Cancer | SpringerLink
Real-world insights into patients with advanced NSCLC and MET alterations - Lung Cancer
Novartis bags FDA priority review in tight lung cancer race against Merck KGaA | Fierce Pharma
Novartis' Powerful MET Inhibitor Tabrecta Has A Strong Therapeutic Effect On METex14 Mutant Non-small Cell Lung Cancer (NSCLC)! - Industry news - News - Hefei Home Sunshine Pharmaceutical Technology Co., Ltd
Safety of Tepotinib in Patients with MET Exon 14 Skipping NSCLC and Recommendations for Management - Clinical Lung Cancer
Schematic representation of MET signaling blockade by capmatinib.... | Download Scientific Diagram
Novartis announces MET inhibitor Tabrecta™ approved in Japan for advanced non-small cell lung cancer with METex14 | Novartis
Capmatinib (INC280) | Selective MET Inhibitor | MedChemExpress
A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor - Journal of Thoracic Oncology
Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer
c-Met inhibitor 1 | ≥99%(HPLC) | c-Met inhibitor | AdooQ®
Novartis beats Merck KGaA to U.S. finish line with targeted lung cancer drug Tabrecta | Fierce Pharma
Novartis Reports Results of Capmatinib in P-II GEOMETRY mono-1 Study for Non-Small Cell
Tabrecta (capmatinib) for the Treatment of Non-Small Cell Lung Cancer
MET-dependent solid tumours — molecular diagnosis and targeted therapy | Nature Reviews Clinical Oncology
Contemporary Developments in MET-Selective Kinase Inhibitors in Advanced Non–Small-Cell Lung Cancer
Biomedicines | Free Full-Text | Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment | HTML
